MicroPort NeuroTech (02172.HK) was founded in 2012 and headquartered in Shanghai Zhangjiang Hi-Tech Park. After many years of development, we have established a comprehensive product portfolio that covers all three major areas of neurovascular diseases, namely hemorrhagic stroke, cerebral atherosclerotic stenosis and acute ischemic stroke (AIS).

As at the end of August 2023, we had 17 products approved by NMPA, and four products admitted to the NMPA’s Innovative Medical Device Special Review and Approval procedure (known as the “Green Path”). Our products are available in over 2,800 hospitals nationwide, providing safe and effective stroke solutions for more than 300,000 patients accumulatively. Meanwhile, we have a leading global strategy and international expansion. Four products have been commercialized in a total of 12 overseas countries, covering five countries ranking top 10 worldwide in terms of the number of neuro-interventional procedures.

Our corporate culture and spirit is captured by the statement “Eyes for Greatness, Hands on Details”.

With the vision of “Building a Super-Conglomerate of People-Centric Enterprises of Emerging Medical Technologies”, we uphold the core values of “Quality, Integrity, Responsibility, Efficiency, Innovation, Pioneering, Dedication and Collaboration”. We strive to provide accessible, top-quality and comprehensive solutions for stroke patients. We work to relentlessly master every detail of our medical technologies to prolong and reshape the lives of patients everywhere.

Our innovation stems from the brand concept of ‘The Patient Always Comes First’. Going forward, we will continue to enhance our innovation capability to provide accessible, top-quality and comprehensive solutions to stroke patients around the world.

On July 15, 2022, MicroPort NeuroTech was successfully listed on the main board of the Hong Kong Stock Exchange with the stock code of 02172.HK.